Abstract
Purpose
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in cancer patients. However, the association of VTE with immunotherapy remains poorly defined. We therefore evaluated the frequency of VTE in patients receiving immunotherapy and tried to determine predisposing factors.
Methods
A total of 133 adult metastatic cancer patients treated with immunotherapy for any cancer between were included. Baseline demographics, ECOG performance status, type of tumors, and baseline blood count parameters were recorded. Possible predisposing factors were evaluated with univariate and multivariate analyses.
Results
The median age was 60 (interquartile range (IQR) 48–66) years, and the median follow-up was 10.1 (IQR 5.8–18.5) months. Renal cell carcinoma (26.3%) and melanoma (24.1%) were most common diagnoses. Fifteen patients (11.3%) had an episode of VTE. Most of the VTEs were diagnosed as pulmonary emboli (10/15; 67%). Eighty percent (12/15) of these VTE cases were detected incidentally. Patients with a baseline ECOG performance status of 1 or more (29.3% of patients) had a significantly increased risk of venous thrombosis (ECOG ≥1 vs. 0, HR: 3.023, 95% CI: 1.011–9.039, p=0.048). Other factors, including patient age, tumor type, body mass index, baseline thrombocyte, neutrophil, and lactate dehydrogenase levels were not significantly associated with VTE risk.
Conclusions
In this study, we observed VTE development in more than 10% of immunotherapy-treated patients and increased VTE risk in patients with poorer ECOG status. With the asymptomatic nature of VTEs in most cases, a high index of suspicion level for VTE is required in patients treated with immunotherapy.
Similar content being viewed by others
Data availability
The data was not reposited in the data repositories.
References
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S et al (2019) Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res 38:268. https://doi.org/10.1186/s13046-019-1266-0
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL et al. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-celllung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-X
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547–1557. https://doi.org/10.1016/s0140-6736(20)30230-0
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC et al (2014) PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319. https://doi.org/10.1056/NEJMoa1411087
Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86–104. https://doi.org/10.3322/caac.21596
Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490–493. https://doi.org/10.1016/j.thromres.2009.12.023
Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–410. https://doi.org/10.1016/s1470-2045(05)70207-2
BLOM JW, Vanderschoot J, Oostindier M, Osanto S, Van Der Meer F et al (2006) Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost 4:529–535
Roopkumar J, Kim AS, Bicky T, Hobbs BP, Khorana AA (2018) Venous thromboembolism in cancer patients receiving immunotherapy. Blood 132:2510–2510. https://doi.org/10.1182/blood-2018-99-116439
Sainz LG, Martínez-Marin V, Lozano DV, Pérez DM, Barbas JP et al (2019) Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: a single institution experience. Ann Oncol 30:v725
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907. https://doi.org/10.1182/blood-2007-10-116327
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17:230. https://doi.org/10.1186/s12877-017-0621-2
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 41:543–603. https://doi.org/10.1093/eurheartj/ehz405
Lutgens E, Seijkens TTP (2020) Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. J Immunother Cancer 8:e000300. https://doi.org/10.1136/jitc-2019-000300
Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J et al (2020) A snapshot of cancer-associated thromboembolic disease in 2018-2019: first data from the TESEO prospective registry. Eur J Intern Med 78:41–49. https://doi.org/10.1016/j.ejim.2020.05.031
Giustozzi M, Curcio A, Weijs B, Field TS, Sudikas S et al (2020) Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost 120:847–856. https://doi.org/10.1055/s-0040-1709527
Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A et al (2019) Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers (Basel) 12. https://doi.org/10.3390/cancers12010067
Nick van E, Marcello Di N, Gabriela C, Ankie K, Hans-Martin O et al (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102:1494–1501. https://doi.org/10.3324/haematol.2017.169060
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature reviews. Clin Oncol 15:325–340. https://doi.org/10.1038/nrclinonc.2018.29
Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, de Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, Caruso V, Bednarek Debruyne M, Bhavsar C, Molinaro AM, Smith T, Severgnini M, Wen PY (2018) Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. In. Proc Am Soc Clin Oncol 6:2006
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905. https://doi.org/10.1056/NEJMoa1915745
Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov A (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. Acta Radiol 55:45–53. https://doi.org/10.1177/0284185113491569
Bozas G, Jeffery N, Ramanujam-Venkatachala D, Avery G, Stephens A et al (2018) Prognostic assessment for patients with cancer and incidental pulmonary embolism. Thromb J 16:8. https://doi.org/10.1186/s12959-017-0157-x
Gutierrez-Sainz L, Martinez-Marin V, Viñal D, Martinez-Perez D, Pedregosa J et al (2020) Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clin Transl Oncol. https://doi.org/10.1007/s12094-020-02515-3
Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH et al (2020) Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. https://doi.org/10.1007/s00520-020-05702-8
Cooksley T, Gupta A, Al-Sayed T, Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer 130:193–197. https://doi.org/10.1016/j.ejca.2020.02.025
Scotté F, Leroy P, Chastenet M, Aumont L, Benatar V et al (2019) Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management. Cancers 11:48. https://doi.org/10.3390/cancers11010048
Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR et al (2014) Thrombosis in ovarian cancer: a case control study. Br J Cancer 110:1118–1124. https://doi.org/10.1038/bjc.2014.3
Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L et al (2015) Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 136:1234–1240. https://doi.org/10.1002/ijc.29076
Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R et al (2017) Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer 116:994–1001. https://doi.org/10.1038/bjc.2017.48
Code availability
N/A
Author information
Authors and Affiliations
Contributions
DCG and ME have planned the work. DCG, MSA, TKS, OHA, HCY, HT, FC, NK, ZA, OD, SK, SA, SY, and ME participated in patient care and data collection. All authors, namely DCG, MSA, TKS, OHA, HCY, HT, FC, NK, ZA, OD, SK, SA, SY, and ME, have made significant and substantive contributions to the reporting of the work. All authors have participated in the review of relevant literature, drafting of the manuscript, and review and revisions of the final draft. DCG, MSA, TKS, and ME have analyzed the data and determined the main conclusions. DCG has prepared the first draft of the manuscript. All authors reviewed and participated in the preparation of the revised and final version of the manuscript. DCG and ME are responsible for the overall content as guarantors. All co-authors qualify the criteria for authorship according to Vancouver protocol.
Corresponding author
Ethics declarations
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hacettepe University.
Consent to participate
N/A
Consent for publication
N/A
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guven, D.C., Aksun, M.S., Sahin, T.K. et al. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Support Care Cancer 29, 5417–5423 (2021). https://doi.org/10.1007/s00520-021-06139-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-021-06139-3